

strains of mice created for the purpose of generating such AlivaMab Mice, are dismissed with prejudice.


3. Ablexis's counterclaim for a declaratory judgment that the '018 patent, and each of its claims, is invalid are dismissed with prejudice.

4. Ablexis acknowledges and agrees that the '018 patent is valid and enforceable.

5. Each party shall bear its own attorneys' fees and costs incurred in connection with the above-captioned action.

SO STIPULATED.

DATED: October 31, 2014


Keith A. Orso
korso@irell.com
IRELL & MANELLA LLP
1800 Avenue of the Stars, Suite 900
Los Angeles, CA 90067-4276
(310) 277-1010

Attorneys for Plaintiff Regeneron
Pharmaceuticals, Inc.

DATED: October 31, 2014


Robert J. Goldman
robert.goldman@ropesgray.com
ROPES & GRAY LLP
1900 University Avenue, 6th Floor
East Palo Alto, CA 94303
(650) 617-4000

Attorneys for Defendant Ablexis, LLC

So ordered.
Ablexis (not Merus) is
dismissed from this case.

11/3/14 K-13.70
LJL